JP2024513906A5 - - Google Patents

Info

Publication number
JP2024513906A5
JP2024513906A5 JP2023561609A JP2023561609A JP2024513906A5 JP 2024513906 A5 JP2024513906 A5 JP 2024513906A5 JP 2023561609 A JP2023561609 A JP 2023561609A JP 2023561609 A JP2023561609 A JP 2023561609A JP 2024513906 A5 JP2024513906 A5 JP 2024513906A5
Authority
JP
Japan
Application number
JP2023561609A
Other languages
Japanese (ja)
Other versions
JPWO2022216624A5 (https=
JP2024513906A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/023347 external-priority patent/WO2022216624A1/en
Publication of JP2024513906A publication Critical patent/JP2024513906A/ja
Publication of JPWO2022216624A5 publication Critical patent/JPWO2022216624A5/ja
Publication of JP2024513906A5 publication Critical patent/JP2024513906A5/ja
Pending legal-status Critical Current

Links

JP2023561609A 2021-04-07 2022-04-04 人工多能性幹細胞からアルファ-ベータt細胞を生成するための組成物および方法 Pending JP2024513906A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163171650P 2021-04-07 2021-04-07
US63/171,650 2021-04-07
PCT/US2022/023347 WO2022216624A1 (en) 2021-04-07 2022-04-04 Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells

Publications (3)

Publication Number Publication Date
JP2024513906A JP2024513906A (ja) 2024-03-27
JPWO2022216624A5 JPWO2022216624A5 (https=) 2025-04-11
JP2024513906A5 true JP2024513906A5 (https=) 2025-04-11

Family

ID=81648457

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023561609A Pending JP2024513906A (ja) 2021-04-07 2022-04-04 人工多能性幹細胞からアルファ-ベータt細胞を生成するための組成物および方法

Country Status (9)

Country Link
US (1) US20220333074A1 (https=)
EP (1) EP4320224A1 (https=)
JP (1) JP2024513906A (https=)
CN (1) CN117441010A (https=)
AR (1) AR125313A1 (https=)
AU (1) AU2022255166A1 (https=)
CA (1) CA3214473A1 (https=)
TW (1) TW202305114A (https=)
WO (1) WO2022216624A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021392032A1 (en) 2020-12-03 2023-06-22 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
US20250066738A1 (en) * 2021-09-07 2025-02-27 Dana-Farber Cancer Institute, Inc. Induced pluripotent stem cells (ipsc), t-cell compositions and methods of use
IL314801A (en) 2022-02-22 2024-10-01 Juno Therapeutics Inc Proteinase 3 (PR3) Chimeric Autoantigen Receptor T Cells and Related Methods and Uses
JP2025522360A (ja) 2022-06-08 2025-07-15 センチュリー セラピューティクス,インコーポレイテッド Cd16変異体およびnkg2dを発現する遺伝子操作した細胞ならびにその使用
KR20250143301A (ko) 2022-11-10 2025-10-01 센츄리 쎄라퓨틱스 인코포레이티드 항-넥틴4 키메라 항원 수용체를 갖는 유전자 조작 세포 및 이의 용도
EP4397680A1 (en) * 2022-12-29 2024-07-10 Keshihua (Nanjing) Biotechnology Co., Ltd Tcr, polypeptide, expression vector, host cell, pharmaceutical composition and method for obtaining tcr
WO2025101938A2 (en) 2023-11-10 2025-05-15 Century Therapeutics, Inc. Genetically engineered cells having multi-transmembrane domain chimeric antigen receptors utilizing g protein-coupled receptor scaffolds, and uses thereof
WO2025106626A1 (en) 2023-11-15 2025-05-22 Century Therapeutics, Inc. Genetically engineered cells expressing c-x-c chemokine receptor type 4, and uses thereof
WO2025237762A1 (en) 2024-05-14 2025-11-20 Englmeier Ludwig Matched t-cells and myeloid cells from cell culture

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344321B1 (en) 1990-06-11 2002-02-05 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
US20040224385A1 (en) 2001-08-20 2004-11-11 Barbas Carlos F Zinc finger binding domains for cnn
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US8574179B2 (en) 2004-09-17 2013-11-05 Stp Swiss Therapeutic Products Ag Enhanced biomechanical stimulation device
DK3399025T3 (da) 2007-03-23 2025-06-16 Wisconsin Alumni Res Found Omprogrammering af somatiske celler
EP3279314A1 (en) 2008-06-04 2018-02-07 Cellular Dynamics International, Inc. Methods for the production of ips cells using non-viral approach
CA2741090C (en) 2008-10-24 2018-10-16 Wisconsin Alumni Research Foundation Pluripotent stem cells obtained by non-viral reprogramming
KR101720961B1 (ko) 2009-02-27 2017-03-29 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 다능성 세포의 분화
EP3222617B1 (en) 2009-03-19 2022-07-06 The Johns Hopkins University Psma-targeting compounds and uses thereof
HUE041436T2 (hu) 2009-12-10 2019-05-28 Univ Minnesota Tal-effektor-közvetített DNS-módosítás
US9206394B2 (en) * 2010-02-03 2015-12-08 The University Of Tokyo Method for reconstructing immune function using pluripotent stem cells
WO2012018933A2 (en) 2010-08-04 2012-02-09 Cellular Dynamics International, Inc. Reprogramming immortalized b cells
WO2012109208A2 (en) 2011-02-08 2012-08-16 Cellular Dynamics International, Inc. Hematopoietic precursor cell production by programming
DE102012006356A1 (de) 2012-03-28 2013-10-02 Audi Ag Kraftfahrzeug, umfassend mehrere aktive oder passive Sicherheitsvorrichtungen
AU2014248119B2 (en) * 2013-04-03 2019-06-20 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted T-cells derived from pluripotent stem cells
WO2015143029A1 (en) 2014-03-18 2015-09-24 The Johns Hopkins University Psma-based molecular-genetic reporter system
KR102654784B1 (ko) 2014-07-18 2024-04-04 사이아스 가부시키가이샤 다능성 줄기세포로부터 세포-기반 면역요법용 t 세포를 유도하는 방법
CN108431211B (zh) 2015-10-20 2026-03-24 富士胶片细胞动力公司 通过遗传编程的多谱系造血前体细胞产生
EP3708587B1 (en) * 2015-11-27 2024-05-22 Cartherics Pty. Ltd. Genetically modified cells and uses thereof
ES2886631T3 (es) 2016-04-15 2021-12-20 Univ Kyoto Método para inducir células T positivas para CD8 específicas de antígeno
SG11201901642XA (en) 2016-08-26 2019-03-28 Baylor College Medicine Constitutively active cytokine receptors for cell therapy
EP3510145A4 (en) 2016-09-06 2020-03-25 The Children's Medical Center Corporation IMMUNCELLS FROM INDUCED PLURIPOTENT STEM CELLS
CA3035075A1 (en) 2016-09-23 2018-03-29 Fred Hutchinson Cancer Research Center Tcrs specific for minor histocompatibility (h) antigen ha-1 and uses thereof
JP7212615B2 (ja) 2016-10-05 2023-01-25 フジフィルム セルラー ダイナミクス,インコーポレイテッド 多能性幹細胞からhlaホモ接合免疫細胞への指向分化方法
EP3607319A1 (en) 2017-04-07 2020-02-12 Juno Therapeutics, Inc. Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
WO2018195175A1 (en) 2017-04-18 2018-10-25 FUJIFILM Cellular Dynamics, Inc. Antigen-specific immune effector cells
CN111432823A (zh) 2017-07-25 2020-07-17 得克萨斯大学体系董事会 增强的嵌合抗原受体及其用途
CA3076099A1 (en) 2017-09-22 2019-03-28 Kite Pharma, Inc. Linkers for chimeric antigen receptors
US20200239544A1 (en) 2017-10-03 2020-07-30 Precision Biosciences, Inc. Modified epidermal growth factor receptor peptides for use in genetically-modified cells
CN112739816B (zh) 2018-09-19 2025-09-12 富士胶片细胞动力公司 用于激活和扩增嵌合抗原受体-修饰的免疫细胞的蛋白l
KR102943217B1 (ko) * 2018-12-02 2026-03-25 페이트 세러퓨틱스, 인코포레이티드 향상된 iPSC 유래 효과기 세포를 사용한 면역요법
JP6821230B2 (ja) * 2019-02-04 2021-01-27 国立大学法人愛媛大学 CARライブラリおよびscFvの製造方法
EP3924467A1 (en) * 2019-02-15 2021-12-22 Editas Medicine, Inc. Modified natural killer (nk) cells for immunotherapy
US12419954B2 (en) * 2020-01-31 2025-09-23 City Of Hope Targeted chimeric antigen receptor modified T cells for treatment of IL13Rα2 positive malignancies

Similar Documents

Publication Publication Date Title
BR102022025291A2 (https=)
BR102023014872A2 (https=)
BR102023012440A2 (https=)
BR102023010976A2 (https=)
BR102023009641A2 (https=)
BR102023008688A2 (https=)
BR102023007252A2 (https=)
BR102023005164A2 (https=)
BR102023001877A2 (https=)
BR102023000289A2 (https=)
BR102022026909A2 (https=)
BR102022023461A2 (https=)
BR202022009269U2 (https=)
BR202022005961U2 (https=)
BR202022001779U2 (https=)
BR202022000931U2 (https=)
BY13149U (https=)
BY13159U (https=)
BY13140U (https=)
BY13141U (https=)
BY13142U (https=)
BY13143U (https=)
BY13144U (https=)
BY13175U (https=)
BY13174U (https=)